A clinical case of asymptomatic pancreatic hyperenzymemia on the background of taking a Glucagon-like peptide-1 analogue (GLP-1)
According to current statistics, the incidence of type 2 diabetes has increased significantly over the past few years. The number of drugs prescribed to correct carbohydrate metabolism is also increasing, and new groups of hypoglycemic drugs are appearing. This prompts a more detailed study and anal...
Saved in:
| Main Authors: | N.A. Sanina, N.O. Hondulenko, S.S. Panina, V.S. Shulha |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dnipro State Medical University
2023-09-01
|
| Series: | Medičnì Perspektivi |
| Subjects: | |
| Online Access: | https://journals.uran.ua/index.php/2307-0404/article/view/289229 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A once-daily GLP-1/GIP/glucagon receptor tri-agonist (NN1706) lowers body weight in rodents, monkeys and humans
by: Brian Finan, et al.
Published: (2025-06-01) -
The Neuroprotective Effects of GLP-1 Analogues on Alzheimer's Disease – A Literature Review
by: Wiktoria Ulicka, et al.
Published: (2025-04-01) -
Perioperative Practice Patterns of Anaesthesiologists Surrounding Glucagon-Like Peptide-1 (GLP-1) Agonist Medications
by: Meghan Brennan, et al.
Published: (2025-04-01) -
Anti-inflammatory effects of glucagon-like peptide-1 (GLP-1) in coronary artery disease: a comprehensive review
by: Alicja Skrobucha, et al.
Published: (2024-12-01) -
Wilson – Konovalov Disease: Clinical Cases with Different Manifestations and Outcomes
by: O. V. Samodova, et al.
Published: (2023-06-01)